🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

15+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 15 of 15 recruiting trials for “Langerhans cell histiocytosis”

NARecruitingNCT07371182 ↗

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

🏥 West China Second University Hospital📍 11 sites📅 Started Jun 2026View details ↗
NARecruitingNCT07431060 ↗

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

🏥 West China Second University Hospital📍 11 sites📅 Started Feb 2026View details ↗
Phase 2RecruitingNCT07022834 ↗

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

👨‍⚕️ Ju Gao, MD, West China Second University Hospital, Sichuan University, Sichuan, China📍 1 site📅 Started Jun 2025View details ↗
Phase 2RecruitingNCT07187193 ↗

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

👨‍⚕️ Xinxin XX Cao, doctor, NCC, CICAMS📍 1 site📅 Started Apr 2025View details ↗
Phase 1Enrolling by InvitationNCT06902792 ↗

Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents

🏥 Second Affiliated Hospital of Wenzhou Medical University📍 1 site📅 Started Feb 2025View details ↗
Phase 2RecruitingNCT06582745 ↗

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

👨‍⚕️ Anish Ray, MD, Cook Children's Health Care System📍 1 site📅 Started Jun 2024View details ↗
Phase 2RecruitingNCT05828069 ↗

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

👨‍⚕️ Carl E Allen, Children's Oncology Group📍 115 sites📅 Started Mar 2024View details ↗
RecruitingNCT06197204 ↗

Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell Histiocytosis

🏥 Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Mar 2024View details ↗
Phase 2RecruitingNCT06078969 ↗

Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

🏥 Shanghai Changzheng Hospital📍 1 site📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT05997602 ↗

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

👨‍⚕️ Rui Zhang, MD, Beijing Children's Hospital,Captial Medical University📍 11 sites📅 Started Sep 2023View details ↗
Phase 3RecruitingNCT04943211 ↗

Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

👨‍⚕️ Anna Raciborska, Mother and Child Institute📍 1 site📅 Started Apr 2021View details ↗
Phase 2RecruitingNCT04943198 ↗

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

👨‍⚕️ Anna Raciborska, Mother and Child Institute📍 1 site📅 Started Apr 2021View details ↗
Phase 3RecruitingNCT04773366 ↗

A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

👨‍⚕️ Yi-Jin Gao, MD, Shanghai Children's Medical Center📍 1 site📅 Started Jul 2018View details ↗
Phase 2, PHASE3RecruitingNCT02205762 ↗

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

👨‍⚕️ Milen Minkov, MD, Ph.D, Children's Cancer Research Institute / St. Anna Children's Hospital📍 42 sites📅 Started Nov 2016View details ↗
Phase 3RecruitingNCT02670707 ↗

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

👨‍⚕️ Olive Eckstein, MD, Baylor College of Medicine📍 11 sites📅 Started Mar 2016View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →